Icure Pharmaceutical Incorporation (175250) — Cash Flow Quality Index
Icure Pharmaceutical Incorporation (175250) has a Cash Flow Quality Index of -689.55x as of December 2024. Operating cash flow of ₩-17.05 Billion is below net income of ₩24.73 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash flow conversion of Icure Pharmaceutical Incorporation to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Icure Pharmaceutical Incorporation Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Icure Pharmaceutical Incorporation across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 175250 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Icure Pharmaceutical Incorporation (2017–2024)
Year-by-year earnings quality comparison for Icure Pharmaceutical Incorporation. For live market cap and the full company financial profile, see Icure Pharmaceutical Incorporation (175250) market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -689.55x | ₩-17.05 Billion | ₩24.73 Million | ▼ -33240.2% |
| 2017 | 2.08x | ₩1.12 Billion | ₩537.95 Million | — |